In silico probing and biological evaluation of SETDB1/ESET-targeted novel compounds that reduce tri-methylated histone H3K9 (H3K9me3) level

ERG-associated protein with the SET domain (ESET/SET domain bifurcated 1/SETDB1/KMT1E) is a histone lysine methyltransferase (HKMT) and it preferentially tri-methylates lysine 9 of histone H3 (H3K9me3). SETDB1/ESET leads to heterochromatin condensation and epigenetic gene silencing. These functional changes are reported to correlate with Huntington’s disease (HD) progression and mood-related disorders which make SETDB1/ESET a viable drug target. In this context, the present investigation was performed to identify novel peptide-competitive small molecule inhibitors of the SETDB1/ESET by a combined in silico–in vitro approach. A ligand-based pharmacophore model was built and employed for the virtual screening of ChemDiv and Asinex database. Also, a human SETDB1/ESET homology model was constructed to supplement the data further. Biological evaluation of the selected 21 candidates singled out 5 compounds exhibiting a notable reduction of the H3K9me3 level via inhibitory potential of SETDB1/ESET activity in SETDB1/ESET-inducible cell line and HD striatal cells. Later on, we identified two compounds as final hits that appear to have neuronal effects without cytotoxicity based on the result from MTT assay. These compounds hold the calibre to become the future lead compounds and can provide structural insights into more SETDB1/ESET-focused drug discovery research. Moreover, these SETDB1/ESET inhibitors may be applicable for the preclinical study to ameliorate neurodegenerative disorders via epigenetic regulation.Graphical Abstract

[1]  Axel Imhof,et al.  Identification of a specific inhibitor of the histone methyltransferase SU(VAR)3-9 , 2005, Nature chemical biology.

[2]  T. Kouzarides.  Histone methylation in transcriptional control. , 2002, Current opinion in genetics & development.

[3]  A. Sali,et al.  Comparative protein structure modeling of genes and genomes. , 2000, Annual review of biophysics and biomolecular structure.

[4]  C. Allis,et al.  Translating the Histone Code , 2001, Science.

[5]  C. Jacob,et al.  Histone Methylation in the Nervous System: Functions and Dysfunctions , 2012, Molecular Neurobiology.

[6]  T. Blundell,et al.  Comparative protein modelling by satisfaction of spatial restraints. , 1993, Journal of molecular biology.

[7]  Yi Zhang,et al.  mAM facilitates conversion by ESET of dimethyl to trimethyl lysine 9 of histone H3 to cause transcriptional repression. , 2003, Molecular cell.

[8]  A. Sali,et al.  Alignment of protein sequences by their profiles , 2004, Protein science : a publication of the Protein Society.

[9]  Scott Horowitz,et al.  Structure and Function of Histone H3 Lysine 9 Methyltransferases and Demethylases. , 2011 .

[10]  J. Thompson,et al.  CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. , 1994, Nucleic acids research.

[11]  Anton Simeonov,et al.  Protein lysine methyltransferase G9a inhibitors: design, synthesis, and structure activity relationships of 2,4-diamino-7-aminoalkoxy-quinazolines. , 2010, Journal of medicinal chemistry.

[12]  Yi Zhang,et al.  Molecular cloning of ESET, a novel histone H3-specific methyltransferase that interacts with ERG transcription factor , 2002, Oncogene.

[13]  Karl Mechtler,et al.  Reversal of H3K9me2 by a small-molecule inhibitor for the G9a histone methyltransferase. , 2007, Molecular cell.

[14]  E. Hamel,et al.  Direct Photoaffinity Labeling of Cysteine-295 of α-Tubulin by Guanosine 5′-Triphosphate Bound in the Nonexchangeable Site* , 1998, The Journal of Biological Chemistry.

[15]  C. D. Krause,et al.  Protein arginine methyltransferases: evolution and assessment of their pharmacological and therapeutic potential. , 2007, Pharmacology & therapeutics.

[16]  D. Eisenberg,et al.  Assessment of protein models with three-dimensional profiles , 1992, Nature.

[17]  Feng Liu,et al.  A chemical probe selectively inhibits G9a and GLP methyltransferase activity in cells. , 2011, Nature chemical biology.

[18]  Ian W. Davis,et al.  Structure validation by Cα geometry: ϕ,ψ and Cβ deviation , 2003, Proteins.

[19]  M. MacDonald,et al.  Dominant phenotypes produced by the HD mutation in STHdh(Q111) striatal cells. , 2000, Human molecular genetics.

[20]  Yan Jiang,et al.  Setdb1-mediated histone H3K9 hypermethylation in neurons worsens the neurological phenotype of Mecp2-deficient mice , 2011, Neuropharmacology.

[21]  Yong Li,et al.  Matrix softness regulates plasticity of tumour-repopulating cells via H3K9 demethylation and Sox2 expression , 2014, Nature Communications.

[22]  Hong Lei,et al.  Histone H3-K9 Methyltransferase ESET Is Essential for Early Development , 2004, Molecular and Cellular Biology.

[23]  Mark T Bedford,et al.  Arginine methylation an emerging regulator of protein function. , 2005, Molecular cell.

[24]  Wolfgang Fischle,et al.  Role of histone modifications in defining chromatin structure and function , 2008, Biological chemistry.

[25]  R. Ferrante,et al.  ESET/SETDB1 gene expression and histone H3 (K9) trimethylation in Huntington's disease , 2006, Proceedings of the National Academy of Sciences.

[26]  Ben M. Webb,et al.  Comparative Protein Structure Modeling Using MODELLER , 2007, Current protocols in protein science.

[27]  S. Grewal,et al.  Regulation of heterochromatin by histone methylation and small RNAs. , 2004, Current opinion in cell biology.

[28]  Andrew Smellie,et al.  Identification of Common Functional Configurations Among Molecules , 1996, J. Chem. Inf. Comput. Sci..

[29]  T. Jenuwein,et al.  An epigenetic road map for histone lysine methylation , 2003, Journal of Cell Science.

[30]  Yu Jin Hwang,et al.  ESET methylates UBF at K232/254 and regulates nucleolar heterochromatin plasticity and rDNA transcription , 2013, Nucleic acids research.

[31]  Andrew L Kung,et al.  Monoallele deletion of CBP leads to pericentromeric heterochromatin condensation through ESET expression and histone H3 (K9) methylation. , 2008, Human molecular genetics.

[32]  Aiming Sun,et al.  Adding a lysine mimic in the design of potent inhibitors of histone lysine methyltransferases. , 2010, Journal of molecular biology.

[33]  Pierre-Olivier Angrand,et al.  The control of histone lysine methylation in epigenetic regulation. , 2007, Biochimie.

[34]  Matthieu Schapira,et al.  Structural Chemistry of Human SET Domain Protein Methyltransferases , 2011, Current chemical genomics.

[35]  A. Sali,et al.  Modeling of loops in protein structures , 2000, Protein science : a publication of the Protein Society.

[36]  Anton Simeonov,et al.  Discovery of a 2,4-diamino-7-aminoalkoxyquinazoline as a potent and selective inhibitor of histone lysine methyltransferase G9a. , 2009, Journal of medicinal chemistry.

[37]  Jon R. Wilson,et al.  SET domains and histone methylation. , 2003, Current opinion in structural biology.

[38]  B. Turner,et al.  Cellular Memory and the Histone Code , 2002, Cell.

[39]  Oliver Korb,et al.  Pose prediction and virtual screening performance of GOLD scoring functions in a standardized test , 2012, Journal of Computer-Aided Molecular Design.

[40]  Valérie Campagna-Slater,et al.  Structural Biology of Human H3K9 Methyltransferases , 2010, PloS one.

[41]  M. Carrasquillo,et al.  Assignment of a novel bifurcated SET domain gene, SETDB1, to human chromosome band 1q21 by in situ hybridization and radiation hybrids , 1999, Cytogenetic and Genome Research.

[42]  C. Ponting,et al.  Regulation of chromatin structure by site-specific histone H3 methyltransferases , 2000, Nature.

[43]  B. Fierz,et al.  Chromatin as an expansive canvas for chemical biology. , 2012, Nature chemical biology.

[44]  C. Qian,et al.  SET domain protein lysine methyltransferases: Structure, specificity and catalysis , 2006, Cellular and Molecular Life Sciences CMLS.

[45]  Andrej ⩽ali,et al.  Comparative protein modeling by satisfaction of spatial restraints , 1995 .